Intravenous Immunoglobulin Market Key Players Analysis - Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel (hospital pharmacies, speciality pharmacies), Region, Market Outlook And Industry Analysis 2031"

The global Intravenous Immunoglobulin market is estimated to reach over USD 21.22 billion by 2031, exhibiting a CAGR of 6.60% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1874

Immunoglobulins are derived from a large human plasma pool, sourced from a minimum of 100 donors. Traditionally, the intramuscular route of administration was employed; however, it has become less favored due to its discomfort. In recent years, intravenous immunoglobulin (IVIG) has proven to be a crucial treatment for individuals with compromised immune systems. The increasing prevalence of target disorders, such as primary immunodeficiency disorders, is anticipated to drive market expansion. Additionally, factors such as the growing incidence of immunodeficiency diseases, advancements in technology and investments, heightened acceptance of immunoglobulin therapy, and an aging population are expected to contribute to revenue growth in the market over the forecast period.

IVIG, a sterile, concentrated solution of antibodies derived from healthy individuals, is administered intravenously to treat immune system disorders or enhance immune response. However, the high cost associated with diagnosing and treating demyelinating diseases presents a significant challenge to market growth. Immunoglobulin infusions are typically administered every 3 to 4 weeks, with treatments repeated 12 to 16 times annually. The cost of IVIG therapy is estimated at USD 73.89 per gram, with an overall treatment expense of approximately USD 10,000, depending on the severity of the patient's condition.

List of Prominent Players in the Intravenous Immunoglobulin Market:
• Biotest AG
• Baxter International Inc.
• Octapharma AG
• LFB Biotechnologies
• Grifols SA
• CSL Behring
• China Biologics Products Inc.
• Kedrion Biopharma
• BDI Pharma Inc

Market Dynamics:
Drivers-
The rise in the geriatric population, the increased acceptance of immunoglobulin treatment, and the growing prevalence of immunodeficiency diseases and bleeding disorders are all key drivers driving the market growth. With new product launches and approvals, the immunoglobulin market is expected to develop in the future. IVIG therapies are in high demand for treating acquired and primary immunodeficiency illnesses since they are the most effective and only viable therapy option. Furthermore, inactive lifestyle practices, such as eating saturated fats, salt, and sweets, as well as a deficiency of physical exercise and excessive alcohol use, have contributed to an increase in the prevalence of these diseases

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Challenges:
The high cost of intravenous immunoglobulin (IVIG) therapy presents a significant barrier to widespread usage, potentially limiting market revenue growth during the forecast period. Additionally, supply chain disruptions could arise from a shortage of raw materials, while stringent regulatory policies across various countries may hinder business expansion. Immunoglobulin therapy, being one of the most advanced and technologically complex treatments, incurs substantial costs. Plasma collection, purification, and scarcity are all expensive processes, exacerbated by the need for advanced technology and adequate healthcare infrastructure. Consequently, the global plasma supply chain remains a persistent challenge in many regions.

Regional Trends:
The North American intravenous immunoglobulin market is expected to capture a significant revenue share and grow at a high compound annual growth rate (CAGR) in the near future. This growth is fueled by the region's well-established and advanced healthcare system, a strong focus on research and development, and the presence of key industry players. Additionally, the Asia Pacific market holds a considerable share, driven by increasing awareness of immunoglobulin-based therapies and the growing need to address primary immunodeficiencies, particularly in an aging population.

Recent Developments:
• In March 2022, Sanofi and Seagen Inc. agreed to work exclusively to discover, develop, and commercialize antibody-drug conjugates (ADCs) targeting up to three cancer targets. Sanofi's unique monoclonal antibody (mAb) technology and Seagen's patented ADC technology will be used in the cooperation.
• In January 2022, Argenx SE, a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, announced that Japan's Ministry of Health, Labour, and Welfare (MHLW) had approved VYVGART (efgartigimod alfa) intravenous infusion for the therapy of adult patients with generalized myasthenia gravis (gMG) who have not answered adequately to steroids or non-steroidal immunosuppressive therapies (ISTs).

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1874

Segmentation of Intravenous Immunoglobulin Market-
By Application-
• Hypogammaglobulinemia
• CIPD
• Immunodeficiency Diseases
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• ITP
• Kawasaki Disease
• Guillain-barre Syndrome
• Others
By Distribution Channel-
• Hospital Pharmacy
• Specialty Pharmacy
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/intravenous-immunoglobulin-market-/1874

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.